Qulipta Side Effects
Generic name: atogepant
Note: This document contains side effect information about atogepant. Some dosage forms listed on this page may not apply to the brand name Qulipta.
Applies to atogepant: oral tablet.
Serious side effects of Qulipta
Along with its needed effects, atogepant (the active ingredient contained in Qulipta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Other side effects of Qulipta
Some side effects of atogepant may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Constipation
- nausea
- sleepiness or unusual drowsiness
- unusual tiredness or weakness
Less common
- Decreased appetite
- decreased weight
Incidence not known
- Chest tightness
- cough
- difficulty swallowing
- dizziness
- fast heartbeat
- hives, itching, skin rash
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- trouble breathing
For Healthcare Professionals
Applies to atogepant: oral tablet.
Gastrointestinal
Common (1% to 10%): Nausea, constipation
General
The more commonly reported adverse reactions have included nausea, constipation, and fatigue.[Ref]
Hepatic
Common (1% to 10%): Liver enzyme elevations[Ref]
Transaminase elevations greater than 3 times the upper limit of normal (3 x ULN) were reported similarly for patients receiving this drug and those receiving placebo (1% vs 1.8%). Temporally associated cases of transaminase elevations were reported with use of this drug; they were asymptomatic and resolved within 8 weeks of discontinuation.[Ref]
Hypersensitivity
Postmarketing reports: Hypersensitivity reactions[Ref]
Metabolic
Common (1% to 10%): Decreased appetite, weight loss
Weight loss of greater than 7% of body weight was reported for 3.8% of patients receiving 10 mg/day, 3.2% for 30 mg/day, and 4.9% for patients receiving 60 mg/day (compared to 2.8% for placebo).
Nervous system
Common (1% to 10%): Somnolence, dizziness[Ref]
Other
Common (1% to 10%): Fatigue[Ref]
Frequently asked questions
- How do Ubrelvy, Qulipta and Nurtec compare for migraines?
- What are the new drugs for the treatment of migraines?
- Does Qulipta cause weight loss?
- How long does Qulipta take to work?
- Does Qulipta (atogepant) cause hair loss?
- When is the best time of the day to take Qulipta?
- How well does Qulipta work for migraine?
- How does Qulipta work?
More about Qulipta (atogepant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (123)
- Drug images
- Dosage information
- During pregnancy
- Support group
- FDA approval history
- Drug class: CGRP inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
References
1. Product Information. Qulipta (atogepant). AbbVie US LLC. 2021.
2. Product Information. Qulipta (atogepant). AbbVie US LLC. 2023;SUPPL-4.
3. Boinpally R, Jakate A, Butler M, Borbridge L< Periclou A. Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. Clin Pharmacol Drug Dev. 2021;10:726-33.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
